Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jun 3;17(6):1578-1585.
doi: 10.1080/21645515.2020.1840887. Epub 2021 Feb 19.

Vaccinia virus-based vector against infectious diseases and tumors

Ziling Zhang  1 , Lanlan Dong  1 , Chen Zhao  1 , Peiyong Zheng  2 , Xiaoyan Zhang  1   3 , Jianqing Xu  1   3
Affiliations
Review

Vaccinia virus-based vector against infectious diseases and tumors

Ziling Zhang et al. Hum Vaccin Immunother. .

Abstract

Vaccinia virus was used to prevent smallpox. After the World Health Organization declared smallpox extinct, vaccinia virus has been explored for the development of vaccines against a variety of infectious diseases. It also finds a new place in oncolytic therapy. Here we provide a brief review of the history, current status, and future prospect of vaccinia virus-based vaccine and oncolytic virus. New advancements, including a single vaccine targeting multiple viruses, strategies of arming vaccinia viruses to enhance anti-tumor activity, the promise and challenge of combining vaccinia-based virotherapy with immunotherapy, are discussed as special focus.

Keywords: Tiantan strain; Vaccinia virus; oncolytic virus; tumor; vaccine vector.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
The history and application of TTV. TTV was isolated from smallpox patients in 1926. TTV passed through three generations in monkeys, five generations in rabbits, three generations in cattle, one to two generations in rabbits and one to three generations in cattle, before becoming the recombinant TTV that is now widely used against many diseases and tumors
Figure 2.
Figure 2.
Construction of recombinant TTV. First, the original TTV infects cells and releases the virus genome; then, the plasmid carrying foreign genes will transfect cells and recombine with the TTV genome, producing the recombinant TTV
See this image and copyright information in PMC

References

    1. Liu MA. Vaccine developments. Nat Med. 1998;4:515–19. doi: 10.1038/nm0598supp-515. - DOI - PubMed
    1. Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov. 2015;14:642–62. doi: 10.1038/nrd4663. - DOI - PMC - PubMed
    1. Koch T, Dahlke C, Fathi A, Kupke A, Krähling V, Okba N, Halwe S, Rohde C, Eickmann M, Volz A, et al. Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial. Lancet Infect Dis. 2020;20:827–38. doi: 10.1016/S1473-3099(20)30248-6. - DOI - PMC - PubMed
    1. Potts KG, Irwin CR, Favis NA, Pink DB, Vincent KM, Lewis JD, Moore RB, Hitt MM, Evans DH. Deletion of F4L (ribonucleotide reductase) in vaccinia virus produces a selective oncolytic virus and promotes anti-tumor immunity with superior safety in bladder cancer models. EMBO Mol Med. 2017;9:638–54. doi: 10.15252/emmm.201607296. - DOI - PMC - PubMed
    1. Scutts SR, Ember SW, Ren H, Ye C, Lovejoy CA, Mazzon M, Veyer DL, Sumner RP, Smith GL. DNA-PK is targeted by multiple vaccinia virus proteins to inhibit DNA sensing. Cell Rep. 2018;25:1953–65. doi: 10.1016/j.celrep.2018.10.034. - DOI - PMC - PubMed

Publication types